Structural determinants of agonist selective signaling at the sst2A somatostatin receptor

Molecular Endocrinology

Volumn 25, Issue 5, 2011, Pages 859-866

  Nagel, Falko ^a   Doll, Christian ^a   Pöll, Florian ^a   Kliewer, Andrea ^a   Schröder, Helmut ^b   Schulz, Stefan ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HORMONE RECEPTOR; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR 2A; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTICLE; CELL STRAIN HEK293; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; G-PROTEIN-COUPLED RECEPTOR KINASES; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OCTREOTIDE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RATS; RECEPTORS, SOMATOSTATIN; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; SOMATOSTATIN;

RATTUS;

EID: 79955777034     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0407     Document Type: Article

References (23)

1. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017
2. Donangelo I, Melmed S 2005 Treatment of acromegaly: future. Endocrine 28:123-128
3. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP 2010 Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742-753
4. van der Hoek J, Lamberts SW, Hofland LJ 2004 The role of somatostatin analogs in Cushing's disease. Pituitary 7:257-264
5. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
6. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46:2334-2344
7. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW 2005 Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 78: 69-80
8. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J 2009 Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
9. Pedroncelli AM 2010 Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Neuroendocrinology 92(Suppl 1):120-124
10. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM 2010 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781-2789
11. Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S 2010 Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24:436-446
12. Liu Q, Bee MS, Schonbrunn A 2009 Site specificity of agonist and second messenger-activated kinases for sst2A somatostatin receptor phosphorylation. Mol Pharmacol 76:68-80
13. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94:654-661
14. Cescato R, Loesch KA, Waser B, Macke HR, Rivier JE, Reubi JC, Schonbrunn A 2010 Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 24:240-249
15. Kobilka BK, Deupi X 2007 Conformational complexity of G-pro-tein-coupled receptors. Trends Pharmacol Sci 28:397-406
16. Rosenbaum DM, Rasmussen SG, Kobilka BK 2009 The structure and function of G-protein-coupled receptors. Nature 459:356-363
17. Wess J, Han SJ, Kim SK, Jacobson KA, Li JH 2008 Conformational changes involved in G-protein-coupled-receptor activation. Trends Pharmacol Sci 29:616-625
18. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S 2008 Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519-4524
19. Pfeiffer M, Koch T, Schröder H, Klutzny M, Kirscht S, Kreienk HJ, Hollt V, Schulz S, 2001 Homo-and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem, 276:14027-14036
20. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S 2004 Differential -arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 279:21374-21382
21. Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88: 5150-5157
22. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203-1210
23. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Höllt V 2000 Immunohistochemical determination of five soma- tostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865-1874